Zobrazeno 1 - 10
of 218
pro vyhledávání: '"Nick H. Kim"'
Autor:
Richard Channick, Kelly M. Chin, Vallerie V. McLaughlin, Matthew R. Lammi, Roham T. Zamanian, Stefano Turricchia, Rose Ong, Lada Mitchell, Nick H. Kim
Publikováno v:
Cardiology and Therapy, Vol 13, Iss 2, Pp 315-339 (2024)
Abstract Introduction Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) are scarce. The OPUS/OrPHeUS studies enrolled patients newly initiating macit
Externí odkaz:
https://doaj.org/article/c4b19ee288354c6089965ac76ad5d6fa
Autor:
Nick H. Kim, Kelly M. Chin, Vallerie V. McLaughlin, Hilary DuBrock, Ricardo Restrepo-Jaramillo, Zeenat Safdar, Gwen MacDonald, Nicolas Martin, Daniel Rosenberg, Maria Solonets, Richard Channick
Publikováno v:
Pulmonary Therapy, Vol 10, Iss 1, Pp 85-107 (2024)
Abstract Introduction Portopulmonary hypertension (PoPH) carries a worse prognosis than other forms of pulmonary arterial hypertension (PAH). Data regarding use of PAH-specific therapies in patients with PoPH are sparse as they are usually excluded f
Externí odkaz:
https://doaj.org/article/d2d527f021da4bc98cd27bae7d4bdc4e
Autor:
Emanuel A. Keiler, Kim M. Kerr, David S. Poch, Jenny Z. Yang, Demosthenes G. Papamatheakis, Mona Alotaibi, Angela Bautista, Victor G. Pretorius, Michael M. Madani, Nick H. Kim, Timothy M. Fernandes
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 2, Pp n/a-n/a (2024)
Abstract Current predictors of clinical outcomes after pulmonary thromboendarterectomy (PTE) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) are largely limited to preoperative clinical characteristics. N‐terminal‐pro‐bra
Externí odkaz:
https://doaj.org/article/5ec74f813f3045e987f9b2a069687eed
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 4, Pp n/a-n/a (2023)
Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by persistent organized thromboembolic obstruction of the pulmonary arteries from incompletely resolved pulmonary embolism. The treatment of choice is pulmonary thromboendartere
Externí odkaz:
https://doaj.org/article/c76824ada7b54539b46d418ae6621ce6
Autor:
Mingmei Xiong, Pritesh P. Jain, Jiyuan Chen, Aleksandra Babicheva, Tengteng Zhao, Mona Alotaibi, Nick H. Kim, Ning Lai, Amin Izadi, Marisela Rodriguez, Jifeng Li, Angela Balistrieri, Francesca Balistrieri, Sophia Parmisano, Xin Sun, Daniela Valdez‐Jasso, John Y‐J. Shyy, Patricia A. Thistlethwaite, Jian Wang, Ayako Makino, Jason X.‐J. Yuan
Publikováno v:
Pulmonary Circulation, Vol 11, Iss 4, Pp 1-17 (2021)
Pulmonary arterial hypertension is a progressive and fatal disease and rodents with experimental pulmonary hypertension (PH) are often used to study pathogenic mechanisms, identify therapeutic targets, and develop novel drugs for treatment. Here we d
Externí odkaz:
https://doaj.org/article/1cc8dfb4cf714cbb804698ca95dfda41
Autor:
Vallerie V. McLaughlin, Richard Channick, Nick H. Kim, Robert P. Frantz, John W. McConnell, Lana Melendres‐Groves, Chad Miller, Ashwin Ravichandran, Josanna Rodriguez‐Lopez, Monika Brand, Sandrine Leroy, Graham Wetherill, Kelly M. Chin
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 4, Pp n/a-n/a (2022)
Abstract Macitentan is an oral endothelin receptor antagonist for the management of pulmonary arterial hypertension (PAH). The OPsumit® USers Registry (OPUS) and the OPsumit® Historical USers cohort (OrPHeUS) medical chart review provide real‐wor
Externí odkaz:
https://doaj.org/article/1ae0250ff48848e6abac30f59f11ea5e
Autor:
David S. Poch, Ehtisham Mahmud, Mitul Patel, Demosthenes Papamatheakis, Timothy Fernandes, Kim Kerr, Jenny Yang, Victor Pretorius, Michael M. Madani, Nick H. Kim
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 4, Pp n/a-n/a (2022)
Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is the result of incompletely resolved pulmonary emboli (PE) that lead to chronic right heart failure. The two mechanical treatment options are pulmonary thromboendarterectomy (PTE) and b
Externí odkaz:
https://doaj.org/article/4630f1a2df3f4bfcb805c45363cef151
Autor:
Ina Jeong, Mona Alotaibi, Timothy M. Fernandes, Suhyun Kim, Kim M. Kerr, Jenny Yang, Victor Pretorius, Michael Madani, Nick H. Kim
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract Patients with chronic thromboembolic pulmonary hypertension (CTEPH) require lifelong anticoagulant therapy. The safety and efficacy of direct oral anticoagulant (DOAC) in the chronic and transitional management of CTEPH has not been investig
Externí odkaz:
https://doaj.org/article/7e01dd920b434d6b8b98fcba640d19d0
Autor:
Jenny Z. Yang, Mazen F. Odish, Hannah Mathers, Nicole Pebley, Gabriel Wardi, Demosthenes G. Papamatheakis, David S. Poch, Nick H. Kim, Timothy M. Fernandes, Rebecca E. Sell
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Over the past 20 years, despite significant advancements in pulmonary arterial hypertension (PAH) medical therapy, many patients require admission to the hospital and are at risk for in‐hospital cardiac arrest (IHCA). Prior data found poor
Externí odkaz:
https://doaj.org/article/a57250a4047441f3a07df00ab371b6aa
Autor:
Stefan Guth, Andrea M. D'Armini, Marion Delcroix, Kazuhiko Nakayama, Elie Fadel, Stephen P. Hoole, David P. Jenkins, David G. Kiely, Nick H. Kim, Irene M. Lang, Michael M. Madani, Hiromi Matsubara, Aiko Ogawa, Jaquelina S. Ota-Arakaki, Rozenn Quarck, Roela Sadushi-Kolici, Gérald Simonneau, Christoph B. Wiedenroth, Bedrettin Yildizeli, Eckhard Mayer, Joanna Pepke-Zaba
Publikováno v:
ERJ Open Research, Vol 7, Iss 3 (2021)
Background Pulmonary endarterectomy (PEA), pulmonary arterial hypertension (PAH) therapy and balloon pulmonary angioplasty (BPA) are currently accepted therapies for chronic thromboembolic pulmonary hypertension (CTEPH). This international CTEPH Regi
Externí odkaz:
https://doaj.org/article/18ed9cff6cfb49e7a57d597ad8bdb811